Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Apr 7, 2023; 29(13): 2015-2033
Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.2015
Table 5 Comparison of responders and virological non-responders to antiviral therapy
Parameter
Responders (n = 3271)
Non-responders (n = 171)
P value
Gender, females/males, n (%)1539 (47)/1732 (53)42 (24.6)/129 (75.4)< 0.0001
Age (yr), mean ± SD; min-max58.0 ± 12.6; 21-9755.0 ± 10.5; 29-840.0002
    Females61.6 ± 11.8; 21-9159.9 ± 10.6; 35-810.3173
    Males54.8 ± 12.4; 21-9753.4 ± 10; 29-840.1045
BMI, mean ± SD; min-max27.4 ± 5.0; 13.4-57.428.7 ± 4.6; 16-47.50.0001
Current treatment regimen
Genotype-specific treatment regimens
    ASV + DCV47 (1.4)8 (4.7)0.0001
    LDV/(SOF ± RBV)748 (22.9)30 (17.5)0.1047
    OBV/PTV/(r ± DSV ± RBV)1052 (32.2)24 (14)< 0.0001
    GZR/(EBR ± RBV)387 (11.8)11 (6.4)0.0314
Pangenotypic regimens
    GLE/PIB420 (12.8)15 (8.8)0.1186
    GLE/(PIB + SOF + RBV)2 (0.1)00.7464
    SOF/(VEL ± RBV)477 (14.6)44 (25.7)0.0001
    VOX/VEL/SOF7 (0.2)00.5448
GT, n (%)< 0.0001
    163 (1.9)2 (1.2)
    1a70 (2.2)1 (0.6)
    1b2624 (80.2)89 (52.0)
    3397 (12.1)76 (44.4)
    4110 (3.4)3 (1.8)
    Other7 (0.2)0
Comorbidities, n (%)
    Any comorbidity2498 (76.4)131 (4)0.9425
    Hypertension1533 (46.9)66 (2)0.0345
    Diabetes731 (22.3)46 (1.4)0.1651
    Renal disease124 (3.8)8 (0.2)0.5558
    Autoimmune diseases63 (1.9)00.0670
    Non-HCC tumors68 (2.1)6 (0.2)0.1963
    Other1783 (54.5)96 (2.9)0.6762
Concomitant medications, n (%)2389 (73.0)136 (79.5)0.0610
Treatment experienced1039 (31.8)69 (40.4)0.0208
History of hepatic decompensation, n (%)
    Ascites297 (9.0)21 (12.2)0.1588
    Encephalopathy65 (2.0)7 (4.1)0.0606
Documented esophageal varices, n (%)780 (23.8)64 (37.4)0.0001
Hepatic decompensation at baseline, n (%)173 (5.3)18 (10.5)0.0035
HCC history, n (%)117 (3.6)9 (5.3)0.2523
OLTx history, n (%)28 (0.9)1 (0.6)0.7052
Child-Pugh class, n (%)
    B or C296 (9)29 (17)0.0006
HBV coinfection (HBsAg+), n (%)50 (1.5)2 (1.2)0.7075
HIV coinfection, n (%)79 (2.4)6 (3.5)0.3690
ALT IU/L, mean ± SD101.2 ± 80.8106.9 ± 82.00.3385
Bilirubin mg/dL, mean ± SD1.1 ± 0.91.2 ± 0.7< 0.0001
Albumin g/dL, mean ± SD4.5 ± 7.73.9 ± 3.10.0002
Creatinine mg/dL, mean ± SD0.9 ± 2.30.8 ± 0.20.8562
Hemoglobin g/dL, mean ± SD14.1 ± 1.813.9 ± 1.80.1319
Platelets, × 1000/μL, mean ± SD132.6 ± 66.8109.2 ± 59.4< 0.0001
HCV RNA × 106 IU/ml, mean ± SD2.2 ± 10.02.0 ± 2.90.1123

  • Citation: Brzdęk M, Zarębska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M, Janocha-Litwin J, Mazur W, Dybowska D, Berak H, Parfieniuk-Kowerda A, Klapaczyński J, Sitko M, Sobala-Szczygieł B, Piekarska A, Flisiak R. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. World J Gastroenterol 2023; 29(13): 2015-2033
  • URL: https://www.wjgnet.com/1007-9327/full/v29/i13/2015.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v29.i13.2015